FILE PHOTO: A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York, U.S., March 24, 2015. REUTERS/Mike Segar/File Photo However, Regeneron still sees a "large opportunity" for Eylea to treat diabetic eye disease and the drugmaker will focus on expanding its label and marketing it with a new TV campaign, company executives said on a conference call with analysts.
https://www.reuters.com/article/us-regeneron-pharms-results/regeneron-posts-quarterly-profit-beat-strongly-backs-eyleas-future-idUSKBN1KN1I3
No comments:
Post a Comment